Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of systemic vasculitis.

C A Langford1

  • 1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

Best Practice & Research. Clinical Rheumatology
|July 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same author

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis and rheumatism·2013
Same author

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Arthritis and rheumatism·2012
Same author

Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.

Clinical and experimental immunology·2011
Same journal

The young adult with Juvenile Idiopathic Arthritis (JIA): A clinical review of transition, complications, and psychosocial management.

Best practice & research. Clinical rheumatology·2026
Same journal

Impact of fatigue on rheumatic diseases: Current perspectives.

Best practice & research. Clinical rheumatology·2026
Same journal

Pneumocystis prophylaxis in rheumatic disease.

Best practice & research. Clinical rheumatology·2026
Same journal

Cutaneous manifestations in myositis syndromes.

Best practice & research. Clinical rheumatology·2026
Same journal

Systemic sclerosis: A comprehensive systematic review of global epidemiology, sex and ethnic disparities, disease burden, and organ-specific involvement.

Best practice & research. Clinical rheumatology·2026
Same journal

Alopecia across the spectrum of rheumatic disease.

Best practice & research. Clinical rheumatology·2026
See all related articles

Systemic vasculitis involves blood vessel inflammation, requiring immunosuppressive therapy. Treatment decisions for vasculitis depend on disease type, severity, and therapeutic effectiveness, balancing risks and benefits.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic vasculitides are diverse diseases defined by blood vessel inflammation.
  • Clinical manifestations and severity vary significantly among vasculitis types.
  • Immunosuppressive therapy is central to managing most systemic vasculitides.

Purpose of the Study:

  • To review the management approach for selected systemic vasculitides.
  • To address critical questions regarding treatment initiation and decision-making.
  • To evaluate the effectiveness of various therapeutic regimens.

Main Methods:

  • Review of management strategies for specific systemic vasculitis forms.
  • Analysis of factors influencing treatment decisions, including disease nature and severity.

Related Experiment Videos

  • Examination of data on the efficacy of individual treatment plans.

    • Main Results:

    • Treatment timing and intensity are dictated by disease characteristics and severity.
    • Immunosuppressive therapy carries inherent risks, including side effects and infections.
    • Effectiveness data guides the selection of appropriate therapeutic regimens.

    Conclusions:

    • Management of systemic vasculitis requires careful consideration of disease specifics.
    • Balancing treatment efficacy with potential morbidity and mortality is crucial.
    • Evidence-based decision-making is essential for optimal patient outcomes in vasculitis care.